Hyperfractionation for head and neck cancer

Parsons, James T.; Mendenhall, William M.; Cassisi, Nicholas J.; Isaacs, John H.; Million, Rodney R.

doi:10.1016/0360-3016(88)90085-5

Cited by 156 publications

(30 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, chemotherapy and radiotherapy often have been integrated employing split-course radiotherapy, where interruptions of all therapy, similar to the administration of chemotherapy in cycles, are introduced to allow for normal tissue recovery. This approach is controversial, since protraction of radiotherapy as a single-treatment modality has been shown to be detrimental [25][26][27][28]. However, the addition of chemotherapy to a split course of radiotherapy may at least compensate for the planned interruption of radiotherapy [29].…”

Section: Intermittent Schedule Of Chemoradiotherapymentioning

confidence: 99%

Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure

et al. 2003

View full text Add to dashboard Cite

Combined modality programs that were developed over the past two decades demonstrated that the nonsurgical therapy of locoregionally advanced head and neck cancer is feasible and produces survival outcomes that are at least comparable with surgery. The systemic therapy of head and neck cancer has gained momentum in recent years. Several randomized studies have shown that the concurrent administration of chemotherapy and radiation therapy is superior to radiation therapy alone. Medicine, 676 North St. Clair Street, Suite 850, Chicago, Illinois 60611, USA. Telephone: 312-695-6180; Fax: 312-695-6189; e-mail: aargiris@northwestern.edu Received December 10, 2002; accepted for publication April 21, 2003. ©AlphaMed Press 1083-7159/2003 The Oncologist ® LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Discuss the results of multicenter trials with chemoradiotherapy with 5-FU-and hydroxyurea-based regimens for the treatment of locoregionally advanced head and neck cancer.2. Explain the rationale for the combination treatment of radiation, 5-FU, and hydroxyurea.3. Recognize the toxicities and potential functional impairment for patients treated with aggressive concurrent chemoradiotherapy.4. Discuss the experimental role of induction chemotherapy in the management of locoregionally advanced head and neck cancer.Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

Section: Intermittent Schedule Of Chemoradiotherapymentioning

confidence: 99%

Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure

et al. 2003

View full text Add to dashboard Cite

show abstract

“…However these better treatment outcomes are associated with increased morbidity worsening quality of life of the patient [2][3][4][5][6][7][8][9][10][11][12][13][14]. HNC patients are more likely to experience nutritional deficiencies during all phases of disease [15][16][17][18][19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Nutritional Management for Patients with Head and Neck Cancer: The Second Step of an Italian Survey. The Opinion of Italian Otolaryngologists

Trignani¹,

Laus²

2016

Otolaryngol

View full text Add to dashboard Cite

show abstract

“…Results have shown improved local-regional control with increase in dose with no increase in late toxicities. Parsons et al [15] estimated an approximate 15% increase in tumor control probability as compared to historical controls with their hyperfractionated schedules for moderately advanced to advanced primary squamous cell carcinomas of head and neck and without any overall increase in late complications. To further delineate whether or not there is a benefi t to hyperfractionation, the RTOG has recently completed a randomized study of hyperfractionation versus conventional fractionation in T 2 squamous cell carcinoma (SCC) of the vocal cord (RTOG 95-12/EORTC 22992).…”

Section: Altered Fractionationmentioning

confidence: 99%

Recent Advances in Radiation Therapy for Head and Neck Cancer

Bangalore

Matthews²,

Suntharalingam³

2006

ORL

View full text Add to dashboard Cite

The treatment of locally advanced or recurrent head and neck cancers has improved from single modality interventions of surgery and radiation therapy alone to include combined modality therapy with surgery, chemotherapy and radiation. Combined therapy has led to improved local control and disease-free survival. New developments in radiation oncology such as altered fractionation, three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, stereotactic radiosurgery, fractionated stereotactic radiotherapy, charged-particle radiotherapy, neutron-beam radiotherapy, and brachytherapy have helped to improve this outlook even further. These recent advances allow for a higher dose to be delivered to the tumor while minimizing the dose delivered to the surrounding normal tissue. This article provides an update of the new developments in radiotherapy in the management of head and neck cancers.

show abstract

Hyperfractionation for head and neck cancer

Cited by 156 publications

References 8 publications

Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure

Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure

Nutritional Management for Patients with Head and Neck Cancer: The Second Step of an Italian Survey. The Opinion of Italian Otolaryngologists

Recent Advances in Radiation Therapy for Head and Neck Cancer

Contact Info

Product

Resources

About